Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. (VTAK) is a U.S.-based medical device company focused on the cardiac electrophysiology market, and its news flow reflects developments around its VIVO 3D imaging system and LockeT suture retention device. The company’s releases highlight product adoption, regulatory milestones, financial updates, and corporate actions relevant to investors and clinicians following VTAK stock.
Recent news has emphasized international expansion for both VIVO and LockeT. Catheter Precision has reported tender wins and first purchase orders for the VIVO system at hospitals such as Albert Szent‑Györgyi Health Centre in Hungary and Dubrava University Hospital in Croatia, following evaluations against competing technologies. For LockeT, the company has announced launches in Switzerland and South Africa, distribution agreements with regional partners, and implementation at major electrophysiology centers, including Mater Private Hospital in Dublin, Ireland.
In addition to commercial updates, Catheter Precision issues releases on financial results, furnished on Form 8‑K, summarizing revenue trends and operating performance for specific quarters and year‑to‑date periods. The company also uses news announcements to discuss regulatory and reimbursement developments that may affect the use of its products, such as changes in procedure coverage for ambulatory surgery centers that it views as relevant to LockeT utilization.
Other news items cover intellectual property developments, including allowance of patents related to ventricular arrhythmia localization and neurostimulation devices, as well as corporate and capital markets events like reverse stock splits, at‑the‑market offering programs, and stockholder meetings. For ongoing insight into VTAK, this news page aggregates these updates so readers can follow Catheter Precision’s product adoption, geographic reach, financial disclosures, and key regulatory or governance events over time.
Catheter Precision (NYSE American: VTAK) reported Q3 2025 revenue of $226,000, up 135% vs Q3 2024, and nine-month revenue of $581,000, up 114% vs YTD 2024.
GAAP net loss for Q3 2025 was $2,251,000, a 45% reduction from Q3 2024; nine-month GAAP net loss was $11,405,000 vs $11,015,000 year‑earlier. Non‑cash charges were $4,232,000 for the nine months.
Commercially, the company cited a Q2 CE Mark for LockeT, growing international interest (Germany, France, Italy, Spain, Portugal, UK, South Africa), five South Africa reorders in October, and the first VIVO purchase order from France. Management said two VIVO clinical studies completed in 2025 delivered clinical evidence supporting VIVO's clinical potential.
Catheter Precision (NYSE/American: VTAK) announced a distribution agreement with FuMedica AG to introduce the LockeT suture retention device to hospitals and clinics across Switzerland, effective October 16, 2025. LockeT is described as a tool to simplify and secure closure of vascular access sites after cardiac procedures, aimed at electrophysiology labs and interventional suites. FuMedica AG will leverage its Swiss clinical relationships and support capabilities to promote LockeT as part of Catheter Precision’s European expansion.
Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology, has received approval for two new patents from the United States Patent and Trademark Office (USPTO).
The first patent, "Methods of Ventricular Arrhythmia Localization Using a 3D Model," will be assigned to Kardionav, a joint venture between Catheter Precision and physicians. The second patent, "Neurostimulation Devices and Methods," focused on improving cardiac ventricular function in heart failure patients, will be assigned to Cardionomix, a majority-owned subsidiary of Catheter Precision.
Catheter Precision (NYSE:VTAK) has secured its first purchase order from Croatia's Dubrava University Hospital following a successful competitive tender bid. The hospital, which treats over 25,000 inpatients and provides healthcare services to more than 400,000 outpatients annually, completed an evaluation of VTAK's VIVO cardiac mapping technology.
Dr. Ivan Zeljkovic, Head of Electrophysiology Lab at Dubrava, praised VIVO's workflow simplicity, mapping accuracy, and potential to enhance procedural efficacy in targeting ventricular arrhythmia locations. This development marks a significant expansion into the European healthcare market for Catheter Precision's cardiac electrophysiology technology.
Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology products, has set September 10th, 2025 as the record date for its upcoming Special Meeting of Stockholders scheduled for October 10th, 2025.
During the meeting, stockholders will vote on two key proposals: increasing the company's authorized shares of common stock and appointing WithumSmith+Brown, PC as the independent auditor for fiscal year 2026. The preliminary proxy statement detailing these matters is expected to be filed with the SEC on September 4th, 2025.
Catheter Precision (NYSE:VTAK) has announced the successful introduction of its LockeT product line into the Italian market, marking its third European country expansion following France and Germany. The first procedures were successfully conducted at ASST Valle Olona Hospital by Dr. Manuela Bianchi.
The company received its first commercial purchase order from Italian distributor Precise Srl following successful product evaluation. This expansion demonstrates growing market acceptance of LockeT, a device designed to streamline closure after catheter ablation procedures while maintaining cost-effectiveness.
Catheter Precision (NYSE:VTAK), a US-based medical device company, has announced the successful completion of its first LockeT procedures in France at CHU Rennes. The procedures were led by Professor Raphael Martins and his team, marking a significant milestone in the company's European expansion.
This development follows the recent CE Mark approval for LockeT, a device designed to improve procedural efficiency and patient outcomes after cardiac ablation procedures. CHU Rennes, which is also a commercial partner for VTAK's VIVO product line, represents the company's growing presence in the European medical device market.
Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology products, has received notification for a new patent issuance from the U.S. Patent and Trademark Office. The patent, titled "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model," enhances the company's VIVO product line.
The new patent adds to Catheter Precision's existing IP portfolio for VIVO, which is designed to help physicians identify ventricular arrhythmias noninvasively before procedures. CEO David Jenkins emphasized the importance of patents and trademarks in their business strategy and their commitment to advancing medical technology for improved patient care.
Catheter Precision (NYSE:VTAK) has initiated enrollment in the LockeT Compare Study, with the first three patients already enrolled. This single-center, physician-initiated study aims to evaluate the safety profile of the LockeT suture retention device compared to internal closure devices.
The study will enroll up to 100 patients and focuses on addressing groin complications after cardiac catheter procedures. Previous clinical data for LockeT has demonstrated safety, effectiveness, and cost reduction benefits while maintaining existing hospital workflows. The device creates hemostasis externally and may potentially reduce thrombotic episodes compared to internal closure mechanisms.
Catheter Precision (NYSE:VTAK) has received regulatory approval for its LockeT suture retention device in the United Kingdom, following its CE Mark approval in May 2025. The company has partnered with HC21, a major UK-based distributor with €180 million in annual revenue and 500+ employees across the UK and Ireland.
The LockeT device is designed to enhance patient comfort, enable earlier discharge after cardiac procedures, and support NHS efforts to reduce waiting lists. The company will distribute the product through HC21's established network, leveraging their existing partnership to bring the innovative cardiac device to the UK healthcare market.